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Introduction
A number of congenital cardiac malformations require
Right Ventricular Outflow Tract (RVOT) reconstruction
with valved conduits as one of the corrective procedures.
These include Tetrology of Fallot (TOF) with Absent
Pulmonary Valve Syndrome (APVS), Truncus Arteriosus
(TA), Pulmonary Atresia with Ventricular Septal Defect (PA-
VSD), Transposition of Great Arteries, Ventricular Septal
Defect with Pulmonary Stenosis, (d-TGA-VSD-PS) and
Aortic Stenosis (AS). The incidence of Congenital Heart
Diseases (CHDs) is 0.8-1/1000. The above-described
malformations make 13-15% of all CHDs, and
approximately 5-6% of them would need a valved conduit
for primary repair.1 Despite numerous studies, the ideal
valved conduit to repair these complex congenital heart
defects is yet to be developed. Porcine xenografts lack
durability, and homografts have shown early
degeneration, lack of availability in small size, and overall
scarcity.2 The recently developed Contegra Bovine Jugular
Vein Conduit (BJVC)3 has been advocated for its off-the-
shelf availability, small sizes and surgical pliability with
favourable early and midterm outcomes in both adult and
paediatric populations.3
In Pakistan, due to non-availability of homografts,
BJVC Contegra is a good option. The Aga Khan
University Hospital (AKUH) was the first in Pakistan to
start using Contegra in 2007. We have already
published our surgical techniques and immediate
outcome;4 and now present midterm results of
Contegra valve conduit in RVOT position based on
echocardiographic evaluation. 
Patients and Methods
The retrospective study comprised 15 Contegra valved
conduits implanted in RVOT position at AKUH, during May
2007 and June 2012 (Table-1).
The patients were divided into diagnostic categories. The
surgical techniques were described in detail in our initial
publication.4 In brief, the lie of Contegra was kept to the
left, pulmonary arteriotomy was extended on to the
branch pulmonary arteries, the defect was then closed
with a patch of Contegra, making sure that there was
intimal contact, but avoiding full thickness bites of
Contegra to preempt stenosis.
Data collection was made from the clinical notes and from
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serial echocardiograms by a single cardiologist. Cardiac
catheterisation and Cardiac magnetic resonance imaging
(MRI) were performed where needed.
The echocardiographic protocol was designed taking in
to consideration the recommendations for evaluation of
prosthetic valves with 2D and Doppler
echocardiography by the American Society of
Echocardiography's guidelines.5,6 These patients were
regularly followed up. Transthoracic Doppler
echocardiography was performed post-operatively and
reviewed periodically. Last followup echocardiograhic
study was done at the time of data collection in June
2012. Maximum Instantaneous Pressure Gradient (MIPG)
across Contegra exceeding 3m/s (PG=36mmHg) was
considered moderate stenosis, and >4 m/s (64mmHg)
with serially increasing velocity was taken as severe
stenosis. Stenosis was further classified as subvalvar,
transvalvar and supravalvar (at the level of distal
anastamosis).
Bio-Prosthetic valve regurgitation was graded as absent,
mild, moderate and severe based on the jet size, density,
deceleration rate and diastolic flow reversal in the
pulmonary artery.4,5 Moderate and severe grade were
taken as functionally significant.
All the conduits were unsupported. Conduit diameter
was measured at the level of the valve, above the
valve, and below the valve. A mean of three
measurements were taken and conduit aneurysm was
defined as conduit dilatation >1.5 fold of initial
diameter. All patients received aspirin post-operatively
for six months.
Descriptive data was analysed using SPSS version 19.0.
Data was divided into categorical and continuous
variables. The categorical variables were expressed in
percentages and frequencies. The continuous variables
were expressed in median with minimum and maximum
values. Non-parametric tests like Wilcoxon Signed Ranks
tests were used. A probability value of <0.05 was taken as
significant.
Results
The median age at surgery was 9 years (range: 2.5-16
years), and the median weight was 15kgs (range: 9-
45kgs). A total of 18 conduits had been implanted
initially, but there were 3 (16.66%) early deaths. Of the
remaining 15 patients, 1 (6.66%) was lost to followup
after immediate post-surgical echocardiographic exam.
Clinical outcome with complete echocardiographic
followup, as such, was available for 14 (93.3%) patients.
Median followup was 24 months (range: 6-60 months).
There were no late deaths.
There was none or minimal MIPG across the conduit
valves in 10 (66%) patients. However, 5 (33%) had
moderate stenosis. Level of stenosis was at the distal
region (supravalvular) in 4 (80%) and at the subvalvular
region in 1 (20%). Two of these 5 (40%) patients had
increase in MIPG up to 50 mmHg over a median period of
18 months (min=12, max=24) after the implantation, with
resultant severe regurgitation and Right Ventricular (RV)
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Table-1: Individual case description (n=15).
S.No. Cardiac Contegra Interval from conduit implantation Surgical Percutanous
diagnosis size to last follow up(months) reintervention intervention
1. dTGA, DORV PA S/P homograft replacement 22 45 No No
2. PA VSD PDA RMBT 22 55 No No
3. PA VSD MBT 20 50 No No
4. TOF APVS PDA 20 60 No No
5. PA VSD RMBT 18 37 No No
6. PA VSD MAPCAS 18 36 No Yes
7. DORV,VSD, d TGA PS 20 31 No No
8. PA VSD MAPCAS 20 24 No No
9. PA VSD MAPCAS 20 23 No Yes
10. AS ROSS 22 22 No No
11. PA VSD MAPCAS 22 16 No No
12. PA VSD MAPCAS 22 14 No No
13. PA VSD MAPCAS 22 6 No No
14. Aortic Stenosis 22 6 No No
15. D TGA DORV PS 22 6 No No
PA: Pulmonary Atresia, VSD: Ventricular Septal Defect, MAPCAS: Main Aortopulmonary Collaterals, DORV: Double Oulet Right Ventricle, PS: Pulmonary Stenosis, d TGA: Transposition of Great vessels, TOF- APVS:
Tetrology Of Fallot with Absent Pulmonary Valve Syndrome. RMBT: Right Modified Blallock Tausing Shunt, PDA: Patent Ductus Arteriosus, AS: Aortic Stenosis.
dysfunction. There was no significant increase in MIPG in
the remaining 3 (60%) patients (p <0.18).
Both patients had an initial diagnosis of PA-VSD with
Main Aortopulmonary Collaterals (MAPCAs) and
hypolastic peripheral PAs . Both underwent cardiac
catheterisation, and one required cardiac MRI, which
revealed proximal and distal bilateral branch PA stenosis
with dilated right-sided cardiac chambers, severe valve
regurgitation with severe RV dysfunction. Conduit valve
was visualised at the distal end with critical Left PA and
severe Right PA (long segment) stenosis distal to the
anastamosis. Both patients required percutanous
reintervention.
Aneurysmal dilataion was taken as >1.5 times in size of
conduit diametre at the time of implantation. The
median diameters of supravalvular, valvular and
subvalvular regions were, 22mm (min=17, max=24);
20mm (min=18, max=22); and 19mm (min=18, max=21)
respectively. At implantation, median conduit size was
22mm (min=18, max=22). There was no evidence of
aneurysmal dilatation. There were no
echocardiographic evidence of calcification, thrombosis
and endocarditis.
Discussion
BJVC, integrating a natural tri-leaflet valve, was first
introduced in 1999 as a clinical alternative with promising
haemodynamic results.7,8We have already published our
data of patients with immediate and early outcome.4 The
current study entailed midterm evaluation of BJVC
performance primarily based on echocardiographic
findings. Our patient population mainly comprised PA-
VSD and MAPCAs (68%) with or without complex
peripheral pulmonary architecture.
The haemodynamic results produced by Contegra in our
patients have been satisfactory; with absent or mild valve
regurgitation in 87% of patients. Similar results have been
reported in literature7,9-13 (Table-2).
None of our patients required surgical replacement of the
conduit, and 87% of them did not need percutaneous
intervention. Brown et al11 reported similar results with
85% of cases not requiring reintervention at a mean
followup of 26 months. Boething et al14 had similar results
and reported no surgical reintervention at 4 years for
Contegra, whereas 20% homografts needed replacement
over the same period. 
However, recent clinical reports on Contegra
performance vary, with some excellent midterm
competence with minimal gradients, whereas other
reports show concerning issues with early stenosis or
conduit insufficiency or both. These discrepancies are
likely due to heterogenous patient population and
variation in techniques. The most widely reported
mechanism of BJVC failure requiring reintervention is
stenosis. Anatomic subgroup with complex branch PAs
are most vulnerable to this failure. Several etiologies
have been proposed for this obstruction, including
inadequate glutaraldehyde removal, kinking from
excessive outflow length of BJVC, distortion by the
ascending aorta from rightward implantation on the PA,
and improper suturing technique leading to
anastamotic stenosis, turbulent blood flow due to
abrupt diameter mismatch from the conduit to
diminutive pulmonary vasculature resulting in intimal
proliferation. A study15 noted excessive neo-intimal
growth at the distal anastamosis, resulting in need for
percutaneous reintervention in 29% and surgical
replacement of conduit in 72% of patients. We
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Table-2: Literature comparison.
Bove21 Corno7 Breymann16 Boudjemline12 Carrel13 Tiete19 Myens15 Shebani17 Study Group
Number of patients 41 67 108 28 22 29 58 62 15
Mean age (years) 1.9±2.6 13.5 4.3±5.2 3.4 2.7 3.4±3.6 9 3.6 8.9±4.1
Mean follow up (months) 12 26.4 25 15 18 10.2±6.4 22.7±10 14 29±4.6
Need for Reintervention 10% 15% 16% 12% 14% 11% 41% 50% 13%
Time in monthsb Na Na 14 Na Na Na Na Na 18
Embolism 0 0 0 0 1 0 3 1 0
Thrombosis Na 0 0 2 0 2 Na 6 0
Aspirin therapy Na All All Nonea all for 3 moths Only for 12 mm conduits None 73% for 6 months All for 6 months
Conduit regurgitation 4.8% 24% 4.6% 3.5% 36% 3.4% 16% 29% 13%
Conduit stenosis 14.6% 0% 7.4% 11% 4.5% 27.6% 50% 10.5% 13%
aAspirin now recommended by authors for all Contegra patients.
bTime interval from implantation to reintervention.
SD: Standard Deviation.
determined that the pulmonary artery should be
patched and the Contegra should be anastomosed to
the patch rather than the artery itself. This helped in
avoiding the contact of direct sheer forces on the
delicate pulmonary artery. We also believed avoiding full
thickness of the Contegra in the lumen, as it could lead
to the development of a neo-intimal peel at the
anastomosed area and maybe a major cause of conduit
obstruction as described by Brown et al.11
Breyman et al published their data of 108 conduits
extending to mean followup of 4 years, with excellent
results.16 However they did not feature PA-VSD
MAPCA's. This subgroup featured in Shebani et al
study17 group (29%) and contributed to 12 (57%) out of
21 reinterventions, making this anatomic group a
significant risk factor for reintervention. The authors
correlated the poor performance of Contegra in this
group to the tendency of these patients to have high
RV/LV pressure ratios postoperatively. Myens et al15 also
reported similar findings, but in smaller sized conduits
ranging from 12-14mm. They, however reported the
discrepancy between the native PA and smaller conduit
size to be the risk factor and not the RV/LV ratio post-
operatively. Rastan et al showed similar results and
suggested that BJVC performed poorly under high
pressure conditions (e.g. peripheral pulmonary
stenosis) and it should be used cautiously in patients in
whom high post-operative RV pressure is anticipated.18
Our results showed an increase in MIPG from 30-50
mmHg at supravalvular region over a period of 18
months (min=12, max=24) in two patients. Both
patients belonged to PA-VSD MAPCAs subgroup with
hypoplastic and complex peripheral PAs. In spite of
abovementioned surgical techniques, they required
early reintervention, which could be related to
hypoplastic distal peripheral PAs.
There was no echocardiographic evidence of
thrombosis and calcification in our study group,
though both have been reported widely in literature.
Biological implants cross-linked with glutaraldehyde,
though protective against calcification, are potentially
thrombogenic. The residual glutaraldehyde released
from the implant hinders colonisation of luminal layer
exposing the implant to thrombogenic process.19
Aspirin therapy is well known to reduce the risk of
thrombosis in vein grafts. Myens[15] and
Boudjemline12 recommend aspirin therapy in all
patients for 6-12 months post-implant.
Contegra conduits have shown good results in
patients who have had previous RVOT reconstruction
with homografts. Immune mediated injury by first
homograft is postulated to be the most significant risk
factor for second homograft failure.20 Two patients in
our group required previous homograft replacement
which were implanted at another centre with
Contegra, and have shown no complication at 45
month followup. 
In terms of limitations, the study had no infant and
literature review emphasises the need for including
them to evaluate the results of smaller Contegra
conduits, specially adequacy of distal anastamosis, on
PA bifurcation. Long-term studies are needed to
ascertain safety, efficacy and durability of BJVC conduit.
Another limitation was the absence of any direct control
group. It would be particularly ideal to evaluate these
BJVC against small homografts in future as a
randomised trial.
Conclusion
Contegra BJVCs have shown satisfactory midterm results
with regards to conduit regurgitation, calcification,
thrombosis, aneurysmal formation with low rates of
percutaneous and surgical interventions. However, PA-
VSD- MAPCAs with hypoplastic PAs subgroup results are
suboptimal and it carries high risk for reintervention. This
subgroup should be cautiously followed. Further analysis
as a larger series and longer followup with better focus on
infants to elucidate the advantage of BJVC in this age
group is also needed.
References
1. Centers for Disease Control and Prevention. Improved national
prevalence estimates for 18 selected major birth defects - United
States, 1999-2001. MMWR Weekly 2006; 54: 1301-5.
2. Christenson JT, Sierra J, Colina Manzano NE, Jolou J, Beghetti M,
Kalangos A. Homografts and xenografts for right ventricular
outflow tract reconstruction: long-term results. Ann Thorac Surg
2010; 90: 1287-93.
3. Herijgers P, Ozaki S, Verbken E, Van Lommel A, Meuris B, Lesaffre E,
et al. Valved jugular vein segments for right ventricular outflow
tract reconstruction in young sheep. J Thorac Cardiovasc Surg
2002; 124: 798-805.
4. Siddiqui MT, Hassan A, Mohsin S, Hamid M, Amanullah MM.
Contegra valved conduit in the pediatric population: an exciting
prospect for right ventricule to pulmonary artery reconstruction;
experience and outcomes at Aga Khan University. J Pak Med Assoc
2012; 62: 1113-7.
5. Novaro GM, Connolly HM, Miller FA. Doppler hemodynamics of 51
clinically and echocardiograohically normal pulmonary valve
prosthesis. Mayo Clin Proc 2001; 76: 155-60.
6. Zoghbi WA, Chambers JB, Dumesnil JG, Foster E, Gottdiener JS,
Grayburn PA, et al. Recommendations for evaluation of prosthetic
valves with echocardiography and Doppler ultrasound. J Am Soc
Echocardiogr 2009; 22: 975-1014.
7. Corno AF, Qandali SD, Serkarski N, Artemisia S, Hurni M, Tozzi P, et
al. Bovine valved xenograft in pulmonary position: medium-term
follow-up with excellent hemodynamics and freedom from
Vol. 63, No. 10, October 2013
Midterm results of bovine jugular vein conduit for right ventricular outflow tract reconstruction 1269
calcification. Ann Thorac Surg 2004; 78: 1382-8.
8. Dave H, Mueggler O, Comber M, Enodien B, Nikolaou G, Bauersfeld
U, et al. Risk factor analysis of 170 single-institutional contegra
implantations in pulmonary position. Ann Thorac Surg 2011; 91:
195-302.
9. Pratap H, Agarwal S, Moharana M, Singh S, Satsangi DK. Right
ventricular outflow tract reconstruction using Contegra® conduit
in Tetrology of Fallot: single centre experience. Indian J Thorac
Cardiovasc Surg 2010; 26: 189-92.
10. Breyman T, Thies WR, Boethig D, Goerg R, Blanz U, Koerfer R.
Bovine valved venous xenografts for RVOT reconstruction: results
after 71 implantations. Eur J Cardiothorac Surg 2002; 21: 703-10.
11. Brown JW, Ruzmetov M, Rodefeld MD, Vijay P, Darragh RK. Valved
bovine jugular vein conduits for right ventricular outflow tract
reconstruction in children: an attractive alternative to pulmonary
homograft. Ann Thorac Surg 2006; 82: 909-16.
12. Boudjemline Y, Bonnet D, Masseh TA, Agnoletti G, Iserin F, Jaubert
F, et al. Use of bovine jugular vein to reconstruct the right
ventricular outflow tract: early results. J Thorac Cardiovasc Surg
2003; 126: 490-7.
13. Boething D, Thies WR, Hecker H, Breymann T. Midterm course after
pediatric right ventricular outflow tract reconstruction: a
comparison of homografts, porcine xenografts and Contegras. Eur
J Cardiothorac Surg 2005; 27: 58-66.
14. Meyns B, Van Grasse L, Boshoff D, Eyskems B, Mertens L, Gewillig
M, et al. The Contegra conduit in the right ventricular out flow
tract induces supravalvular stenosis. J Thorac Cardiovas Surg 2004;
128: 834-40.
15. Breymann T, Boething D, Gerog R, Thies WR. The Contegra bovine
valved vein conduit for pediatric RVOT reconstruction: 4 years
experience with 108 patients. J Card Surg 2004; 19: 426-31.
16. Shebani SO, McGuirk S, Baghai M, Stickley J, De Giovanni JV,
Bu'lock FA, et al. Right ventricular outflow tract reconstruction
using Contegra valved conduit: natural history and conduit
performance under pressure. Eur J Cardiothorac Surg 2006; 29:
397-405.
17. Rastan AJ, Walther T, Daehnert I, Hambsch J, Mohr FW, Janousek J,
et al. Bovine jugular vein conduit for right ventricular outflow tract
reconstruction: evaluation of risk factors for midterm outcome.
Ann Thorac Surg 2006; 82: 1308-15.
18. Tiete AR, Sachweh S, Roemer U, Kozlik-Fieldmann R, Reuchart B,
Daebritz S. Right ventricular outflow tract reconstruction with the
Contegra jugular vein conduit: a word of caution. Ann Thorac Surg
2004; 77: 2151-6.
19. Elkins RC. Is tissue-engineered heart valve replacement clinically
applicable? Curr Cardiol Rep 2003; 5: 125-8.
20. Bové T, Demanet H, Wauthy P, Goldestein JP, Dessey H, Viart P, et al.
Early results of valved bovine jugular vein conduit versus bicuspid
homograft for right ventricular out flow tract reconstruction. Ann
Thorac Surg 2002; 74: 536-41.
J Pak Med Assoc
1270 S. S. Mohsin, M. T. Siddiqui, A. S. Shaikh, et al.
